The invention relates to methods of treating cancer using novel heterocyclic glutaminase inhibitor compounds conjointly with a PD1 or PD-L1 inhibitor.

Provided herein, in some embodiments, are anti-N-gly-canase 1 antibodies and methods of use.

It has been discovered that NAD.sup.+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.

Disclosed are methods for determining the efficacy of a pharmacotherapy drug for kidney cancer using a blood test. The methods include the evaluation of the effect of a drug therapy for the treatment of kidney cancer by measuring the PARK7 level in a blood sample taken from a patient with kidney cancer who receives the drug therapy for the treatment of kidney cancer. An increased PARK7 level indicates that the drug therapy is not effective. Moreover, by using the blood PARK7 level as an indicator, the efficacy of a candidate substance for a therapeutic agent for kidney cancer can also be determined.

The present invention provides methods and compositions for glycan analysis of complex solutions, including proteins and cells in a biological sample. The method includes the preparation of substrates for the capture of proteins and cells for multiplexed analysis. Cells and proteins may be captured by antibody arrays, culture, or direct deposition. The invention further relates to the use of protein and cell glycan analysis in the diagnosis and screening of disease states and disease progression.

Provided herein are methods and kits related to use of vanin-1 (VNN1) expression for assessing responsiveness to steroid treatment in subjects with asthma and for treating subjects with asthma.

Disclosed herein are methods of using an immobilized substrate, immobilized ligand, and a fusion protein of an enzyme for the substrate and a receptor for the ligand, where the immobilized substrate can react to form an immobilized product that has a different mass than the immobilized substrate, and using this transformation to indirectly determine the binding of the receptor and the ligand. These methods can be used for high-throughput screening for possible modulators (e.g., inhibitors or activators) of the ligand-receptor interaction.

The invention provides compositions and systems that allow the sensitive determination of the level of creatinine in a particular solution. Through the optimisation of enzymatic methods to detect creatinine the real-time determination of creatinine levels and creatinine clearance rates are also provided, allowing the real-time monitoring of kidney function. This is considered to be useful both in the monitoring of live subjects, and in the monitoring of isolated organs, such as a kidney, intended for transplantation.

The instant invention provides workflows for the design and characterization of mechanism-based sirtuin modulating compounds, including new or improved sirtuin activating compounds. Workflows for the design of mechanism-based sirtuin activating compounds are provided, based on conditions that must be satisfied by activators if they are to exploit the common catalytic mechanism of all sirtuin enzymes and hence increase catalytic efficiency for any sirtuin and any substrate.

A method for quantitatively determining the amount of acetaminophen in a sample with greater precision, greater sensitivity and fewer interactions and fewer spectral and chemical interferences with other compounds contained in the sample. The method includes acetaminophen being hydrolyzed and the resulting p-minophenol being reacted with a compound of general formula (III)

##STR00001##

in the presence of an oxidant, wherein R1 and R2, independently of one another, are selected from H, CH.sub.3, and OCH.sub.3, R3 is C.sub.2H.sub.5 and R4 is a C.sub.1-4 alkyl moiety with a terminal sulfonate group, with the proviso that at least one of R1 and R2 is OCH.sub.3 and/or R4 additionally has at least one OH substituent, and then the amount of the compound of general formula (IV) in the reaction mixture being photometrically determined.